Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 42: 1168-1175, 1996;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gomez, B.
Right arrow Articles by Kung, V. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gomez, B., Jr
Right arrow Articles by Kung, V. T.

Clinical Chemistry, Vol 42, 1168-1175, Copyright © 1996 by American Association for Clinical Chemistry

Monoclonal antibody assay for free urinary pyridinium cross-links

B Gomez Jr, S Ardakani, BJ Evans, LD Merrell, DK Jenkins and VT Kung
Metra Biosystems, Inc., Mountain View, CA 94043, USA.

The pyridinium cross-links of collagen, pyridinoline (Pyd) and deoxypyridinoline (Dpd), provide structural integrity and rigidity to collagen fibrils in bone. During bone degradation (resorption), the cross-links are released into the circulation and eventually excreted in urine. Pyridinium cross-link measurements in urine have been shown to be sensitive and specific indicators of resorption by both established HPLC and newer enzyme immunoassay (EIA) techniques. We have developed a monoclonal antibody that preferentially binds to the non- peptide-bound free forms of Pyd & Dpd. We have incorporated the antibody conjugated to alkaline phosphatase in a competitive EIA by using Pyd-coated microtiter strip wells. After a 3-h incubation of sample and antibody-enzyme conjugate, color is developed for 1 h with p- nitrophenyl phosphate as the substrate. The intraassay (n = 52) CVs were 3.0-7.6%, and interassay (n = 8) CVs were 6.1-7.4%. Comparisons of the assay (y) with HPLC (x) and a polyclonal antibody-based EIA (x') gave regression equations of y = 0.46x + 4, r = 0.96, and y = 0.56x' + 8, r = 0.96. The EIA detected increased Pyd & Dpd concentrations in urine from postmenopausal women and patients with osteoporosis, hyperthyroidism, hyperparathyroidism, and Paget disease of bone. EIA concentrations also reflected the reduction in Pyd&Dpd excretion resulting from estrogen replacement in surgically menopausal women. Measurement of pyridinium cross-links with this simple EIA appears to provide an accurate index of the rate of resorption and may be useful for metabolic bone disease assessment and monitoring the effects of antiresorptive therapy.


The following articles in journals at HighWire Press have cited this article:


Home page
 Clin. Chem.Home page
M. Sarno, H. Powell, G. Tjersland, D. Schoendorfer, H. Harris, K. Adams, P. Ogata, and G. R. Warnick
A Collection Method and High-Sensitivity Enzyme Immunoassay for Sweat Pyridinoline and Deoxypyridinoline Cross-Links
Clin. Chem., September 1, 1999; 45(9): 1501 - 1509.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
J. D. Clemens, M. V. Herrick, F. R. Singer, and D. R. Eyre
Evidence that serum NTx (collagen-type I N-telopeptides) can act as an immunochemical marker of bone resorption
Clin. Chem., November 1, 1997; 43(11): 2058 - 2063.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
I. Fermo, C. Arcelloni, E. Casari, and R. Paroni
Urine Pyridinium Cross-Links Determination by Beckman Cross Links Kit
Clin. Chem., November 1, 1997; 43(11): 2186 - 2187.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1996 by the American Association for Clinical Chemistry.